WILKES NSG 533 ADVANCED PHARMACOLOGY FINAL EXAM 2026/2027 | 150
VERIFIED QUESTIONS & ANSWERS | INSTANT DOWNLOAD PDF
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1–20)
Question 1
Which pharmacokinetic process primarily determines the onset of a drug’s effect after oral
administration?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale: Absorption is the movement of a drug from the site of administration into the systemic
circulation. For oral drugs, the rate and extent of absorption largely determine how quickly the drug
reaches therapeutic plasma concentrations and produces an effect. Distribution, metabolism, and
excretion affect duration and intensity, but onset is most directly tied to absorption.
Question 2
A drug with a high first-pass effect will have which characteristic when administered orally?
A. Increased bioavailability
B. Decreased bioavailability
C. No change in bioavailability
D. Increased half-life
Correct Answer: B
Rationale: First-pass metabolism occurs in the liver and gut wall before the drug reaches systemic
circulation. A drug with a high first-pass effect has a significant portion metabolized before reaching
target tissues, reducing oral bioavailability. Such drugs may require higher oral doses or alternative
routes.
Question 3
Which parameter reflects the volume of plasma from which a drug is completely removed per unit of
time?
A. Volume of distribution
B. Half-life
,C. Clearance
D. Bioavailability
Correct Answer: C
Rationale: Clearance is the volume of plasma cleared of drug per unit time. It reflects the efficiency
of drug removal by organs such as the liver and kidneys. Volume of distribution describes drug
distribution, half-life describes time to reduce concentration by half, and bioavailability describes
fraction reaching systemic circulation.
Question 4
A drug with a narrow therapeutic index requires:
A. No monitoring
B. Routine serum level monitoring
C. Higher doses
D. Shorter dosing intervals
Correct Answer: B
Rationale: Narrow therapeutic index drugs have small differences between therapeutic and toxic
concentrations. Examples include digoxin, lithium, warfarin, and phenytoin. Serum levels and clinical
response should be monitored closely to avoid toxicity or therapeutic failure.
Question 5
Which statement best describes a competitive antagonist?
A. It binds to the receptor and activates it
B. It binds to the receptor and prevents agonist binding, but can be overcome by increasing agonist
concentration
C. It permanently inactivates the receptor
D. It binds to a different site and enhances agonist effects
Correct Answer: B
Rationale: A competitive antagonist reversibly binds to the same receptor site as the agonist. Its
effects can be overcome by increasing the concentration of the agonist. Noncompetitive antagonists
cannot be overcome by increasing agonist concentration.
Question 6
Which phase of clinical trials primarily assesses safety and dosage in healthy volunteers?
A. Phase I
B. Phase II
,C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I trials typically involve a small number of healthy volunteers and focus on safety,
tolerability, and pharmacokinetics. Phase II assesses efficacy in patients, Phase III compares with
standard treatment, and Phase IV is post-marketing surveillance.
Question 7
A patient with cirrhosis may require lower doses of hepatically metabolized drugs because:
A. Hepatic metabolism is increased
B. Hepatic metabolism is decreased
C. Renal excretion is increased
D. Protein binding is increased
Correct Answer: B
Rationale: Cirrhosis reduces hepatic enzyme activity and blood flow, decreasing metabolism of many
drugs. This can lead to drug accumulation and toxicity. Doses often need reduction, and hepatically
cleared drugs should be used cautiously.
Question 8
Which cytochrome P450 enzyme is most commonly involved in psychotropic drug metabolism?
A. CYP1A2
B. CYP2D6
C. CYP2E1
D. CYP3A4
Correct Answer: B
Rationale: CYP2D6 metabolizes many antidepressants, antipsychotics, and beta-blockers. Genetic
polymorphisms can make patients poor, intermediate, extensive, or ultrarapid metabolizers, affecting
drug levels and response.
Question 9
A patient taking a CYP3A4 inhibitor should be monitored for:
A. Decreased levels of CYP3A4 substrates
B. Increased levels of CYP3A4 substrates
C. No change in CYP3A4 substrates
D. Increased renal clearance
, Correct Answer: B
Rationale: CYP3A4 inhibitors decrease metabolism of substrate drugs, increasing their plasma levels
and risk of toxicity. Common inhibitors include ketoconazole, erythromycin, clarithromycin, and
grapefruit juice.
Question 10
Which statement about protein binding is correct?
A. Only free drug is pharmacologically active
B. Bound drug is pharmacologically active
C. Protein binding increases drug elimination
D. Protein binding decreases drug distribution
Correct Answer: A
Rationale: Only unbound (free) drug can cross membranes and interact with receptors. Highly
protein-bound drugs have a large bound fraction, but only the free fraction is active. Displacement by
another drug can increase free levels and effects.
Question 11
A drug with a half-life of 12 hours will reach steady state in approximately:
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives. For a 12-hour half-life, this is
48–60 hours. Steady state is important for assessing therapeutic response and obtaining serum levels.
Question 12
Which of the following best describes a loading dose?
A. A dose given to maintain steady state
B. A larger initial dose given to rapidly achieve therapeutic levels
C. A dose given only for toxicity
D. A dose given at the end of therapy
Correct Answer: B
VERIFIED QUESTIONS & ANSWERS | INSTANT DOWNLOAD PDF
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1–20)
Question 1
Which pharmacokinetic process primarily determines the onset of a drug’s effect after oral
administration?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale: Absorption is the movement of a drug from the site of administration into the systemic
circulation. For oral drugs, the rate and extent of absorption largely determine how quickly the drug
reaches therapeutic plasma concentrations and produces an effect. Distribution, metabolism, and
excretion affect duration and intensity, but onset is most directly tied to absorption.
Question 2
A drug with a high first-pass effect will have which characteristic when administered orally?
A. Increased bioavailability
B. Decreased bioavailability
C. No change in bioavailability
D. Increased half-life
Correct Answer: B
Rationale: First-pass metabolism occurs in the liver and gut wall before the drug reaches systemic
circulation. A drug with a high first-pass effect has a significant portion metabolized before reaching
target tissues, reducing oral bioavailability. Such drugs may require higher oral doses or alternative
routes.
Question 3
Which parameter reflects the volume of plasma from which a drug is completely removed per unit of
time?
A. Volume of distribution
B. Half-life
,C. Clearance
D. Bioavailability
Correct Answer: C
Rationale: Clearance is the volume of plasma cleared of drug per unit time. It reflects the efficiency
of drug removal by organs such as the liver and kidneys. Volume of distribution describes drug
distribution, half-life describes time to reduce concentration by half, and bioavailability describes
fraction reaching systemic circulation.
Question 4
A drug with a narrow therapeutic index requires:
A. No monitoring
B. Routine serum level monitoring
C. Higher doses
D. Shorter dosing intervals
Correct Answer: B
Rationale: Narrow therapeutic index drugs have small differences between therapeutic and toxic
concentrations. Examples include digoxin, lithium, warfarin, and phenytoin. Serum levels and clinical
response should be monitored closely to avoid toxicity or therapeutic failure.
Question 5
Which statement best describes a competitive antagonist?
A. It binds to the receptor and activates it
B. It binds to the receptor and prevents agonist binding, but can be overcome by increasing agonist
concentration
C. It permanently inactivates the receptor
D. It binds to a different site and enhances agonist effects
Correct Answer: B
Rationale: A competitive antagonist reversibly binds to the same receptor site as the agonist. Its
effects can be overcome by increasing the concentration of the agonist. Noncompetitive antagonists
cannot be overcome by increasing agonist concentration.
Question 6
Which phase of clinical trials primarily assesses safety and dosage in healthy volunteers?
A. Phase I
B. Phase II
,C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I trials typically involve a small number of healthy volunteers and focus on safety,
tolerability, and pharmacokinetics. Phase II assesses efficacy in patients, Phase III compares with
standard treatment, and Phase IV is post-marketing surveillance.
Question 7
A patient with cirrhosis may require lower doses of hepatically metabolized drugs because:
A. Hepatic metabolism is increased
B. Hepatic metabolism is decreased
C. Renal excretion is increased
D. Protein binding is increased
Correct Answer: B
Rationale: Cirrhosis reduces hepatic enzyme activity and blood flow, decreasing metabolism of many
drugs. This can lead to drug accumulation and toxicity. Doses often need reduction, and hepatically
cleared drugs should be used cautiously.
Question 8
Which cytochrome P450 enzyme is most commonly involved in psychotropic drug metabolism?
A. CYP1A2
B. CYP2D6
C. CYP2E1
D. CYP3A4
Correct Answer: B
Rationale: CYP2D6 metabolizes many antidepressants, antipsychotics, and beta-blockers. Genetic
polymorphisms can make patients poor, intermediate, extensive, or ultrarapid metabolizers, affecting
drug levels and response.
Question 9
A patient taking a CYP3A4 inhibitor should be monitored for:
A. Decreased levels of CYP3A4 substrates
B. Increased levels of CYP3A4 substrates
C. No change in CYP3A4 substrates
D. Increased renal clearance
, Correct Answer: B
Rationale: CYP3A4 inhibitors decrease metabolism of substrate drugs, increasing their plasma levels
and risk of toxicity. Common inhibitors include ketoconazole, erythromycin, clarithromycin, and
grapefruit juice.
Question 10
Which statement about protein binding is correct?
A. Only free drug is pharmacologically active
B. Bound drug is pharmacologically active
C. Protein binding increases drug elimination
D. Protein binding decreases drug distribution
Correct Answer: A
Rationale: Only unbound (free) drug can cross membranes and interact with receptors. Highly
protein-bound drugs have a large bound fraction, but only the free fraction is active. Displacement by
another drug can increase free levels and effects.
Question 11
A drug with a half-life of 12 hours will reach steady state in approximately:
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives. For a 12-hour half-life, this is
48–60 hours. Steady state is important for assessing therapeutic response and obtaining serum levels.
Question 12
Which of the following best describes a loading dose?
A. A dose given to maintain steady state
B. A larger initial dose given to rapidly achieve therapeutic levels
C. A dose given only for toxicity
D. A dose given at the end of therapy
Correct Answer: B
